Akari Therapeutics (AKTX) Long-Term Deferred Tax (2022 - 2023)
Akari Therapeutics (AKTX) reported Long-Term Deferred Tax of $42.2 million for Q4 2023, up 22.03% on a YoY basis from $34.6 million in Q4 2022, and up 22.03% sequentially from $34.6 million in Q4 2022.
Akari Therapeutics (AKTX) Long-Term Deferred Tax (2022 - 2023) Analysis & Trends
Akari Therapeutics (AKTX) has 2 years of Long-Term Deferred Tax data on file, last reported at $42.2 million in Q4 2023.
- For the quarter ending Q4 2023, Long-Term Deferred Tax rose 22.03% year-over-year to $42.2 million; the trailing twelve-month figure through Dec 2023 stood at $42.2 million (up 22.03% YoY), and the FY2023 full-year result was $42.2 million, up 22.03% from the prior year.
- Long-Term Deferred Tax climbed to $42.2 million in Q4 2023, from $34.6 million in the prior quarter.
- In the past five years, Long-Term Deferred Tax ranged from a high of $42.2 million in Q4 2023 to a low of $34.6 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 42.24 Mn |
| Dec 31, 2022 | 34.62 Mn |